Gan & Lee Pharmaceuticals, a biopharmaceutical company specializing in insulin and insulin analogues in China, announced that it has entered into an agreement to commercialize three insulin analogs to Sandoz, a division of Swiss drugmaker Novartis with a focus on biosimilar pharmaceuticals. Under this collaboration, Gan & Lee has granted Sandoz the commercialization right of […]

China’s Biopharma Firm Gan & Lee Teams Up With Novartis In Global Insulin Push appeared first on China Money Network.